These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

408 related articles for article (PubMed ID: 27974549)

  • 1.
    Ho DWH; Chan LK; Chiu YT; Xu IMJ; Poon RTP; Cheung TT; Tang CN; Tang VWL; Lo ILO; Lam PWY; Yau DTW; Li MX; Wong CM; Ng IOL
    Gut; 2017 Aug; 66(8):1496-1506. PubMed ID: 27974549
    [TBL] [Abstract][Full Text] [Related]  

  • 2. p53 haploinsufficiency and increased mTOR signalling define a subset of aggressive hepatocellular carcinoma.
    Luo YD; Fang L; Yu HQ; Zhang J; Lin XT; Liu XY; Wu D; Li GX; Huang D; Zhang YJ; Chen S; Jiang Y; Shuai L; He Y; Zhang LD; Bie P; Xie CM
    J Hepatol; 2021 Jan; 74(1):96-108. PubMed ID: 32738450
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Loss of Tuberous Sclerosis Complex 2 (TSC2) Is Frequent in Hepatocellular Carcinoma and Predicts Response to mTORC1 Inhibitor Everolimus.
    Huynh H; Hao HX; Chan SL; Chen D; Ong R; Soo KC; Pochanard P; Yang D; Ruddy D; Liu M; Derti A; Balak MN; Palmer MR; Wang Y; Lee BH; Sellami D; Zhu AX; Schlegel R; Huang A
    Mol Cancer Ther; 2015 May; 14(5):1224-35. PubMed ID: 25724664
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Dampened VEPH1 activates mTORC1 signaling by weakening the TSC1/TSC2 association in hepatocellular carcinoma.
    Dong P; Wang X; Liu L; Tang W; Ma L; Zeng W; Sun S; Zhang L; Zhang N; Shen X; Janssen HLA; Dong L; Zhang S; Chen S
    J Hepatol; 2020 Dec; 73(6):1446-1459. PubMed ID: 32610114
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Rapamycin and CCI-779 inhibit the mammalian target of rapamycin signalling in hepatocellular carcinoma.
    Hui IC; Tung EK; Sze KM; Ching YP; Ng IO
    Liver Int; 2010 Jan; 30(1):65-75. PubMed ID: 19845851
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Rap_GAP Domain of
    Cui M; Jiang W; Sheng J; Wu J; Zhang X
    DNA Cell Biol; 2022 Feb; 41(2):215-224. PubMed ID: 35143341
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Sirolimus-based immunosuppression improves the prognosis of liver Transplantation Recipients with low TSC1/2 expression in hepatocellular carcinoma beyond the Milan Criteria.
    Ye Q; Ling S; Jiang G; Shan Q; Xu S; Zhan Q; Wu Y; Liu Y; Zheng S; Xu X
    Eur J Surg Oncol; 2021 Oct; 47(10):2533-2542. PubMed ID: 33902956
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Advanced sporadic renal epithelioid angiomyolipoma: case report of an extraordinary response to sirolimus linked to TSC2 mutation.
    Espinosa M; Roldán-Romero JM; Duran I; de Álava E; Apellaniz-Ruiz M; Cascón A; Garrigos C; Robledo M; Rodriguez-Antona C
    BMC Cancer; 2018 May; 18(1):561. PubMed ID: 29764404
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Differentiating the mTOR inhibitors everolimus and sirolimus in the treatment of tuberous sclerosis complex.
    MacKeigan JP; Krueger DA
    Neuro Oncol; 2015 Dec; 17(12):1550-9. PubMed ID: 26289591
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Deficient TSC1/TSC2-complex suppression of SOX9-osteopontin-AKT signalling cascade constrains tumour growth in tuberous sclerosis complex.
    Jin F; Jiang K; Ji S; Wang L; Ni Z; Huang F; Li C; Chen R; Zhang H; Hu Z; Zha X
    Hum Mol Genet; 2017 Jan; 26(2):407-419. PubMed ID: 28013293
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Rapamycin regulates the proliferation of Huh7, a hepatocellular carcinoma cell line, by up-regulating p53 expression.
    Kwon S; Jeon JS; Ahn C; Sung JS; Choi I
    Biochem Biophys Res Commun; 2016 Oct; 479(1):74-9. PubMed ID: 27616194
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Neurogenin 3-directed cre deletion of Tsc1 gene causes pancreatic acinar carcinoma.
    Ding L; Han L; Li Y; Zhao J; He P; Zhang W
    Neoplasia; 2014 Nov; 16(11):909-17. PubMed ID: 25425965
    [TBL] [Abstract][Full Text] [Related]  

  • 13. PTEN expression and mutations in TSC1, TSC2 and MTOR are associated with response to rapalogs in patients with renal cell carcinoma.
    Roldan-Romero JM; Beuselinck B; Santos M; Rodriguez-Moreno JF; Lanillos J; Calsina B; Gutierrez A; Tang K; Lainez N; Puente J; Castellano D; Esteban E; Climent MA; Arranz JA; Albersen M; Oudard S; Couchy G; Caleiras E; Montero-Conde C; Cascón A; Robledo M; Rodríguez-Antona C; García-Donas J;
    Int J Cancer; 2020 Mar; 146(5):1435-1444. PubMed ID: 31335987
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Chronic activation of mTOR complex 1 is sufficient to cause hepatocellular carcinoma in mice.
    Menon S; Yecies JL; Zhang HH; Howell JJ; Nicholatos J; Harputlugil E; Bronson RT; Kwiatkowski DJ; Manning BD
    Sci Signal; 2012 Mar; 5(217):ra24. PubMed ID: 22457330
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Interleukin-6-stimulated progranulin expression contributes to the malignancy of hepatocellular carcinoma cells by activating mTOR signaling.
    Liu F; Zhang W; Yang F; Feng T; Zhou M; Yu Y; Yu X; Zhao W; Yi F; Tang W; Lu Y
    Sci Rep; 2016 Feb; 6():21260. PubMed ID: 26879559
    [TBL] [Abstract][Full Text] [Related]  

  • 16. mTORC1 Up-Regulates GP73 to Promote Proliferation and Migration of Hepatocellular Carcinoma Cells and Growth of Xenograft Tumors in Mice.
    Chen X; Wang Y; Tao J; Shi Y; Gai X; Huang F; Ma Q; Zhou Z; Chen H; Zhang H; Liu Z; Sun Q; Peng H; Chen R; Jing Y; Yang H; Mao Y; Zhang H
    Gastroenterology; 2015 Sep; 149(3):741-52.e14. PubMed ID: 25980751
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Point mutations of the mTOR-RHEB pathway in renal cell carcinoma.
    Ghosh AP; Marshall CB; Coric T; Shim EH; Kirkman R; Ballestas ME; Ikura M; Bjornsti MA; Sudarshan S
    Oncotarget; 2015 Jul; 6(20):17895-910. PubMed ID: 26255626
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Tuberous sclerosis complex inactivation disrupts melanogenesis via mTORC1 activation.
    Cao J; Tyburczy ME; Moss J; Darling TN; Widlund HR; Kwiatkowski DJ
    J Clin Invest; 2017 Jan; 127(1):349-364. PubMed ID: 27918305
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Efficacy of combined inhibition of mTOR and ERK/MAPK pathways in treating a tuberous sclerosis complex cell model.
    Mi R; Ma J; Zhang D; Li L; Zhang H
    J Genet Genomics; 2009 Jun; 36(6):355-61. PubMed ID: 19539245
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Heterozygous inactivation of tsc2 enhances tumorigenesis in p53 mutant zebrafish.
    Kim SH; Kowalski ML; Carson RP; Bridges LR; Ess KC
    Dis Model Mech; 2013 Jul; 6(4):925-33. PubMed ID: 23580196
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 21.